{"id":"az-3102-dose-1","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL602200","moleculeType":"Small molecule","molecularWeight":"356.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZ-3102 works by selectively inhibiting the RORγt pathway, which is involved in the regulation of inflammatory responses and has been implicated in various autoimmune diseases. This inhibition leads to a reduction in the production of pro-inflammatory cytokines and other mediators of inflammation.","oneSentence":"AZ-3102 is a selective inhibitor of the retinoic acid receptor-related orphan receptor gamma t (RORγt) pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:06.923Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Moderate to severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT05758922","phase":"PHASE2","title":"Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients with GM2 Gangliosidosis or Niemann-Pick Type C Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Azafaros A.G.","startDate":"2023-04-24","conditions":"GM2 Gangliosidosis, Niemann-Pick Disease, Type C","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7357,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["nizubaglustat"],"phase":"phase_3","status":"active","brandName":"AZ-3102 (Dose 1)","genericName":"AZ-3102 (Dose 1)","companyName":"Azafaros A.G.","companyId":"azafaros-a-g","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZ-3102 is a selective inhibitor of the retinoic acid receptor-related orphan receptor gamma t (RORγt) pathway. Used for Moderate to severe plaque psoriasis, Moderate to severe atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}